Distinct In Vitro Binding Profile of the Somatostatin Receptor Subtype 2 Antagonist [¹⁷⁷Lu]Lu-OPS201 Compared to the Agonist [¹⁷⁷Lu]Lu-DOTA-TATE

• Main Authors: Rosalba Mansi (Author), Pascale Plas (Author), Georges Vauquelin (Author), Melpomeni Fani (Author)
• Format: Book
• Published: MDPI AG, 2021-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Treatment of neuroendocrine tumours with the radiolabelled somatostatin receptor subtype 2 (SST₂) peptide agonist [¹⁷⁷Lu]Lu-DOTA-TATE is effective and well-established. Recent studies suggest improved therapeutic efficacy using the SST<sub>2</su...